UnitedHealth Group Inc (UNH) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

UnitedHealth Group Inc (UNH)

411.04

+2.52 (0.62%)

as of Jun 15, 2026, 8:00:00 pm Market Open.

287 watching

Investor Insights

Jun 14, 2026, 12:00 am

This summary was created by AI, based on 43 opinions in the last 12 months.

UnitedHealth Group Inc (UNH-N) has faced considerable challenges over the past year, reflected in its declining stock price and regulatory scrutiny. Experts note that while the company is fundamentally strong with significant vertical integration in the U.S. healthcare system, it has been impacted by rising medical costs, regulatory pressures, and changes in Medicare reimbursement rates. The new CEO’s leadership is viewed as a positive factor that could guide the company through its current difficulties, but many analysts express caution due to the speculative nature of recent issues and the stock's volatility. Some believe the downturn creates buying opportunities, suggesting that long-term growth may be achievable if operational concerns are resolved. Overall, the sentiment is mixed, with a few experts optimistic about potential recovery while others advise caution until more clarity emerges.

Consensus

Cautious

Valuation

Undervalued

Similar

Cvs, CVS

TOP PICK

They are the largest Health Care provider in the US. He thinks it is going back into the $300 territory after the election. P/E is 17. (Analysts’ price target is $287.72)

DON'T BUY

Basically an insurance provider. Healthcare space in general is messy. Trump is attacking healthcare companies. Insurance costs are rising, but they can't keep going up when wages aren't increasing. So insurance is trying to move down the food chain. Plus, Amazon is getting into the business. He'd be really nervous.

TOP PICK

A managed care company. Like a large medical insurance company, but they own their own facilities and networks. A shock when it sold off. Valuation is fantastic. Once in a decade buying opportunity. Yield is 1.55%. (Analysts’ price target is $288.54)

BUY

Trading at 17 times forward earnings. 13-14% growth rate. 1.5% dividend yield. 15 billion dollar worth of free cash flow. They are in pharmacy and benefit management service. They are have scale across different segments. Good for an uncertain time despite the politics.

BUY ON WEAKNESS

Good operator. Sensible balance sheet. Like the "Home Depot" of healthcare. Difficult to buy on price. Well run. Always at a premium price, as it's a good company.

TOP PICK

Just tested the 50- and 100-week moving averages--and hasn't broken them. It's still cheap after selling off, building a base and is now moving up.

WAIT

Start a position at $240? Positives: top-shelf management with a history of returning 50% of free cash flow each year through dividends and stock buys. They're massive and have cost advantage. Cons: in consolidation now. He takes a longer view on UNH, but wouldn't buy it now. There's no rush to. UNH is also beta. Numbers solid, but UNH isn't cheap. Watch it.

BUY

On a 12 months basis it is better than 85% of the companies in the NYSE. Healthcare has come back quite nicely. This is trading well above a rising 150 day average. This is a theme you can depend on. Managed Healthcare. Continue to hold it.

BUY ON WEAKNESS

It has characteristics of a defensive nature but grows at double digit earnings each year. There are headwinds in that space. Amazon may be entering the pharmacy business. But people are living longer and will need health care longer. Buy it on dips.

COMMENT

18X foward earnings. ROE is 20% average over 5 five years. Healthcare gies you (Analysts’ price target is $301.58)

TOP PICK

It's #5 in revenue of all US companies. They'll do $250 billion in revenue in 2019. It's down only 7-8% during this market carngage, so it's held its own. The CEO belives they just started a growth boom. Has a good runway ahead, working closely with government agencies and in South America. Good defensive stock. (Analysts’ price target is $304.74)

WATCH

They are just so consistent. The health care sector is just so influenced by politics. But these guys reduce costs for governments. This stock has been spectacular. They have scale and a phenomenal management team that returns capital to shareholders. He would not buy more at this time.

BUY

Looks very strong. The technical strength is strong. PEG ratio is 1.4. Likes it. Longer term, 1 year, 24 months this is a good place to be.

TOP PICK

They've had a great run and are the poster child of the U.S. health insurance space. They continue to put up 15% bottom-line growth. (Analysts’ price target is $304.74)

TOP PICK

Healthcare is a fantastic bull market. They have a great chart, in atrong uptrend since 2014 with higher highs and higher lows. (Analysts’ price target is $300.87)

Showing 196 to 210 of 285 entries

Most Recent Experts

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Gordon Reid

GoodReid Investment Counsel

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

UnitedHealth Group Inc (UNH)